spacer
home > pmps > autumn 2018 > to connect, or not to connect?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

To Connect, or Not to Connect?

Billions of dollars are wasted each year due to healthcare solutions noncompliance. With the challenges healthcare budgets face (an ageing population and an increasing number of chronic conditions to name a few), how can patients better manage their health? While making a device connected is not a magic bullet to improve compliance and health, they present some clear benefits. How does one decide if a device should be smart, connected, or neither? Clear questions must be asked before deciding if a device should be connected or not. The categories of needs which define this include: engagement, competence, onboarding, re-onboarding, and more. These should be identified by exploring both connected and non-connected solutions, after which, the solutions to whether a product is connected or not becomes clearer.

In the regulated world of healthcare, the true cost of a connected solution is high and not just financially. Patient attitudes around sharing their health data must be considered, and the benefits they receive should be worthwhile for providing that information.

Understanding the Problem

Many stakeholders are involved in delivering and managing a patient’s therapy. These range from the patient, the caregivers, and healthcare professionals who deliver the care, through to the pharmacist who dispenses the therapy, the payer who funds it, and, not forgetting, the pharmaceutical company that developed it. Each of these stakeholders has different needs and desires, which may or may not be satisfied through the use of a connected medical device. For example, a pharma company may want to ensure that their clinical trials run smoothly so that the therapy is successful, effective, and meets the needs of the regulators. Healthcare professionals want better clinical outcomes for patients, and, ultimately, the patient wants to have their therapy funded and to be able to manage their condition successfully.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Charlotte Harris is a Senior Consultant at Team Consulting whose work typically focusses on managing the strategic and creative ‘front-end’ of the product development process. She has over 20 years’ experience in the medical device industry and has worked in clinical, start-up, and consultancy environments. Charlotte studied medical engineering and has a BEng from Cardiff University, UK, and an MSc from Kings College London, UK.

Tom Etheridge is an Industrial Design Consultant at Team Consulting who uses his experience to deliver holistic support to design, engineering, and human factors groups. He has a degree in industrial design technology from Brunel University, UK, and has worked in a design consultancy environment since graduating in 2010. Tom has been the lead industrial designer on several projects ranging from medical devices to consumer electronics.

Paul Greenhalgh heads Team Consulting’s design group. He is a passionate advocate of the importance of ‘good design’ and is involved in all stages of product development, from front-end innovation to detailed design for manufacture.
spacer
Charlotte Harris
spacer
spacer
spacer
Tom Etheridge
spacer
spacer
spacer
Paul Greenhalgh
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Temperature Controlled Logistics returns with a top schedule for 2019

The 18th annual Temperature Controlled Logistics Conference will bring together supply chain, logistics and quality experts from around the globe to experience four days of ‘unmissable’ workshops, case studies, panels, interactive discussion groups and technology showcases.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement